Advanced glycation end-products and their receptor-mediated roles: Inflammation and oxidative stress

Iranian Journal of Medical Sciences

Volumn 36, Issue 3, 2011, Pages 154-166

  Younessi, Parisa ^a,b   Yoonessi, Ali ^c,d  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b UNIVERSITY OF CANBERRA   (Australia)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Advanced glycation end producs; Inflammation; Oxidative stress; Receptor for advanced glycation end products; Signaling pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT ANTIBODY; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; ANTIOXIDANT; APIGENIN; ASCORBIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYTOKINE; HYALURONIC ACID; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYPHENOL DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROTEIN ANTIBODY; PROTEIN S100B; REACTIVE OXYGEN METABOLITE; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL SURVIVAL; COGNITIVE DEFECT; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG STRUCTURE; GLYCATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; MACROPHAGE ACTIVATION; MICROGLIA; MOLECULAR INTERACTION; NEUROFIBRILLARY TANGLE; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SPLICING; SENILE PLAQUE; SIGNAL TRANSDUCTION;

EID: 80955135583     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Kikuchi S, Shinpo K, Takeuchi M, et al. Glycation--a sweet tempter for neuronal death. Brain Res Brain Res Rev 2003; 41: 306-23.
2. Sattarahmady N, Moosavi-Movahedi AA, Habibi-Rezaei M, et al. Detergency effects of nanofibrillar amyloid formation on glycation of human serum albumin. Carbohydr Res 2008; 343: 2229-34.
3. Sattarahmady N, Moosavi-Movahedi AA, Ahmad F, et al. Formation of the molten globule-like state during prolonged glycation of human serum albumin. Biochim Biophys Acta 2007; 1770: 933-42.
4. Münch G, Lüth HJ, Wong A, et al. Crosslinking of [alpha]-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 2000; 20: 253-7.
5. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 2005; 38: 103-15.
6. Danehy JP. Maillard reactions: nonenzymatic browning in food systems with special reference to the development of flavor. Adv Food Res 1986; 30: 77-138.
7. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006; 11: 646-54
8. Cooper ME. Importance of advanced glycation end products in diabetesassociated cardiovascular and renal disease. Am J Hypertens 2004; 17: 31S-38S.
9. Hennessey PJ, Ford EG, Black CT, Andrassy RJ. Wound collagenase activity correlates directly with collagen glycosylation in diabetic rats. J Pediatr Surg 1990; 25: 75-8.
10. Scalbert P, Birlouez-Aragon I. Relationship Between Lens Protein Glycation and Membrane Structure in Human Cataract. Exp Eye Res 1993; 56: 335-40.
11. Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer's disease: Is IGF1-R the common culprit? Neurobiol Aging 2008; 29: 795-811.
12. Rondeau P, Navarra G, Cacciabaudo F, et al. Thermal aggregation of glycated bovine serum albumin. Biochim Biophys Acta 2010; 1804: 789-98.
13. Malloy P, Tremont G, Grace J, Frakey L. The Frontal Systems Behavior Scale discriminates frontotemporal dementia from Alzheimer's disease. Alzheimers Dement 2007; 3: 200-3.
14. Evans DA. Estimated Prevalence of Alzheimer's Disease in the United States. Milbank Q 1990; 68: 267-89.
15. Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiology of Aging 1996; 17: 921-33.
16. Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation endproducts and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313.
17. Hoppmann S, Steinbach J, Pietzsch J. Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. Int J Biochem Cell Biol 2010; 42: 651-61.
18. Hofmann MA, Drury S, Fu C, et al. RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/ Calgranulin Polypeptides. Cell 1999; 97: 889-901.
19. Alarcón R, Fuenzalida C, Santibáñez M, von Bernhardi R. Expression of Scavenger Receptors in Glial Cells: Comparing the Adhesion of Astrocytes and Microglia from Neonatla Rats to Surface-Bound β-Amyloid. J Biol Chem 2005; 280: 30406-15.
20. Tsoporis JN, Izhar S, Huttunen HJ, Parker TG. S100b induces myocyte apoptosis via a signaling pathway that includes rage, Erk1/2-p38 Mapk and p53. Journal of Molecular and Cellular Cardiology 2007; 42: S81.
21. Shen CP, Tsimberg Y, Salvadore C, Meller E. Activation of Erk and JNK MAPK pathways by acute swim stress in rat brain regions. BMC Neurosci 2004; 5: 36.
22. Liu Y, Liang C, Liu X, et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-κB pathways. Atherosclerosis 2010; 208: 34-42.
23. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011; 32: 763-77.
24. Kalea AZ, Reiniger N, Yang H, et al. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009; 23: 1766-74.
25. Talts JF, Andac Z, Göhring W, et al. Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, [alpha]-dystroglycan and several extracellular matrix proteins. EMBO J 1999; 18: 863-70.
26. Lopez AJ. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet 1998; 32: 279-305.
27. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. J Transl Med 2009; 7: 17.
28. Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 2005; 373: 67-72.
29. Hanford LE, Enghild JJ, Valnickova Z, et al. Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE). J Biol Chem 2004; 279: 50019-24.
30. Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: Association with oxidative stress. Free Radic Biol Med 2007; 43: 511-8.
31. Ghidoni R, Benussi L, Glionna M, et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Trans 2008, 115: 1047-50.
32. Xie J, Reverdatto S, Frolov A, et al. Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE). J Biol Chem 2008; 283: 27255-69.
33. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: An update. Biochimica et Biophysica Acta (BBA). Biochim Biophys Acta 2009; 1793: 993-1007.
34. Osawa M, Yamamoto Y, Munesue S, et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochimica et Biophysica Acta (BBA). Biochim Biophys Acta 2007; 1770: 1468-74.
35. Ostendorp T, Weibel M, Leclerc E, et al. Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris. Biochem Biophys Res Commun 2006; 347: 4-11.
36. Basta G, Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
37. Grossin N, Wautier MP, Meas T, et al. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 2008; 34: 392-5.
38. Chen YS, Yan W, Geczy C, et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009; 11: R39.
39. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227-31.
40. Bopp C, Hofer S, Weitz J, et al. sRAGE is Elevated in Septic Patients and Associated With Patients Outcome. J Surg Res 2008; 147: 79-83.
41. Norata GD, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009; 19: 129-34.
42. Nakamura K, Yamagishi S, Adachi H. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-14.
43. Schmidt AM. Suppression of accelerated diabetic atherosclerosis by soluble receptor for age (sRAGE). Biomedecine & Pharmacotherapy 1998; 52: 321.
44. Kaji Y, Usui T, Ishida S, et al. Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products. Invest Ophthalmol Vis Sci 2007; 48: 858-65.
45. White JA, Manelli AM, Holmberg KH, et al. Differential effects of oligomeric and fibrillar amyloid-[beta]1-42 on astrocytemediated inflammation. Neurobiol Dis 2005; 18: 459-65.
46. Salminen A, Ojala J, Kauppinen A, et al. Inflammation in Alzheimer's disease: Amyloid- β oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009; 87: 181-94.
47. Deane R, Wu Z, Zlokovic BV. RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid β-Peptide Clearance Through Transport Across the Blood-Brain Barrier. Stroke 2004; 35: 2628-31.
48. Wegiel J, Imaki H, Wang K-C, et al. Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Brain Res 2004; 1022: 19-29.
49. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6: 1219-25.
50. Moser B, Wendt TM, Ankersmit JH, et al. Blockade of receptor for age (RAGE) suppresses T lymphocyte proliferation in mixed lymphocyte culture. The Journal of Heart and Lung Transplantation 2003; 22: S100.
51. Peterszegi G, Molinari J, Ravelojaona V, et al. Effect of advanced glycation endproducts on cell proliferation and cell death. Pathol Biol (Paris) 2006; 54: 396-404.
52. Kobayashi T, Oku H, Komori A, et al. Advanced glycation end products induce death of retinal neurons via activation of nitric oxide synthase. Exp Eye Res 2005; 81: 647-54.
53. Berbaum K, Shanmugam K, Stuchbury G, et al. Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008; 41: 198-203.
54. Higai K, Shimamura A, Matsumoto K. Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 2006; 367: 137-43.
55. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin. Int J Cardiol 2010; 142: 273-8.
56. Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009; 207: 597-602.
57. Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Coregulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010; 31: 665-77.
58. Donato R, Sorci G, Riuzzi F, et al. S100B's double life: Intracellular regulator and extracellular signal. Biochimica et Biophysica Acta (BBA). Biochim Biophys Acta 2009; 1793: 1008-22.
59. Scheuren N, Jacobs M, Ertl G, et al. Cyclooxygenase-2 in Myocardium Stimulation by Angiotensin-II in Cultured Cardiac Fibroblasts and Role at Acute Myocardial Infarction. J Mol Cell Cardiol 2002; 34: 29-37.
60. Nah SS, Choi IY, Lee CK, et al. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2008; 47: 425-31.
61. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of Cyclooxygenase-2 Expression in Monocytes by Ligation of the Receptor for Advanced Glycation End Products. J Biol Chem 2003; 278: 34834-44.
62. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287: L774-L783.
63. Kokkola R, Andersson A, Mullins G. RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages. Scand J Immunol 2005; 61: 1-9.
64. Zhang H, Park Y, Wu J, et al. Role of TNFalpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219-30.
65. Dimopoulos N, Piperi C, Psarra V, et al. Increased plasma levels of 8-iso-PGF2 [alpha] and IL-6 in an elderly population with depression. Psychiatry Res 2008; 161: 59-66.
66. Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso- PGF2α using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem 2007; 40: 1297-304
67. Rondeau P, Singh NR, Caillens H, et al. Oxidative stresses induced by glycoxidized human or bovine serum albumin on human monocytes. Free Radic Biol Med 2008; 45: 799-812.
68. Mukherjee TK, Mukhopadhyay S, Hoidal JR. The role of reactive oxygen species in TNFα- dependent expression of the receptor for advanced glycation end products in human umbilical vein endothelial cells. Biochimica et Biophysica Acta (BBA). Biochim Biophys Acta 2005; 1744: 213-23.
69. Basta G, Lazzerini G, Massaro M, et al. Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses. Circulation 2002; 105: 816-22.
70. Belch JJF, Shaw JW, Kirk G, et al. The White Blood Cell Adhesion Molecule ESelectin Predicts Restenosis in Patients With Intermittent Claudication Undergoing Percutaneous Transluminal Angioplasty. Circulation 1997; 95: 2027-31.
71. Ishihara K, Tsutsumi K, Kawane S, et al. The receptor for advanced glycation endproducts (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550: 107-13.
72. Origlia N, Righi M, Capsoni S, et al. Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-α-Mediated Cortical Synaptic Dysfunction. J Neurosci 2008; 28: 3521-30.
73. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol 2003; 183: 394-405.
74. Ito S, Sawada M, Haneda M, et al. Amyloid- [beta] peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells. FEBS Lett 2005; 579: 1995-2000.
75. Hermani A, De Servi B, Medunjanin S, et al. S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 2006; 312: 184-97.
76. Yan X, Wu Xiao C, Sun M, et al. N uclear factor kappa B activation and regulation of cyclooxygenase type-2 expression in human amnion mesenchymal cells by interleukin- 1beta. Biol Reprod 2002; 66: 1667-71.
77. Ito S, Sawada M, Haneda M, et al. Amyloid- β peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006; 56: 294-9.
78. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999; 71: 479-500.
79. Fukunaga K, Miyamoto E. Role of MAP kinase in neurons. Mol Neurobiol 1998; 16: 79-95.
80. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie 2006; 54: 405-19.
81. Sabbagh MN, Agro A, Bell J, et al. PF- 04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. Alzheimer Dis Assoc Disord 2010: 28.
82. Bro S, Flyvbjerg A, Binder CJ, Pallotta G. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 2008; 201: 274-80.
83. Ferretti G, Bacchetti T, Masciangelo S, et al. Lipid peroxidation in hemodialysis patients: Effect of vitamin C supplementation. Clin Biochem 2008; 41: 381-6.
84. Johnston JB, Rahman MM, McFadden G. Strategies that modulate inflammasomes: insights from host-pathogen interactions. Semin Immunopathol 2007; 29: 261-74.
85. Dueñas AI, Aceves M, Orduña A, et al. Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS. Int Immunol 2006; 18: 785-95.
86. Reyes-Gibby CC, Wu X, Spitz M, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008; 9: 777-85.
87. Heremans H, Van Damme J, Dillen C, et al. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzmanlike shock reactions in mice. J Exp Med 1990; 171: 1853-69.
88. Heremans H, Dijkmans R, Sobis H, et al. Regulation by interferons of the local inflammatory response to bacterial lipopol ysaccharide. J Immunol 1987; 138: 4175-9.
89. Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 2002; 41: 1163-7.
90. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience 2009; 158: 1021-9.
91. Lee JS, Oh TY, Kim YK, et al. Protective effects of green tea polyphenol extracts against ethanol-induced gastric mucosal damages in rats: Stress-responsive transcription factors and MAP kinases as potential targets. Mutat Res 2005; 579: 214-24.
92. Nichols J, Katiyar S. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010; 302: 71-83.
93. Jeong GS, Lee SH, Jeong SN, et al. Antiinflammatory effects of apigenin on nicotineand lipopolysaccharide-stimulated human periodontal ligament cells via heme oxygenase-1. Int Immunopharmacol 2009; 9: 1374-80.
94. Li BH, Ma XF, Wang Y, Tian WX. Structure- Activity Relationship of Polyphenols That Inhibit Fatty Acid Synthase. J Biochem 2005; 138: 679-85.
95. Gilliam-Davis S, Payne VS, Kasper SO, et al. Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol 2007; 293: H1327-H1333.
96. Natarajan R, Nadler JL. Lipid Inflammatory Mediators in Diabetic Vascular Disease. Arterioscler Thromb Vasc Biol 2004; 24: 1542-8.
97. Maillard-Lefebvre H, Boulanger E, Daroux M, et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009; 48: 1190-6.
98. Neumann A, Schinzel R, Palm D, et al. High molecular weight hyaluronic acid inhibits advanced glycation endproductinduced NF-[kappa]B activation and cytokine expression. FEBS Letters 1999; 453: 283-7.
99. Neill SJ, Desikan R, Clarke A, et al. Hydrogen peroxide and nitric oxide as signalling molecules in plants. J Exp Bot 2002; 53: 1237-47.
100. Orozco-Cardenas ML, Ryan CA. Nitric Oxide Negatively Modulates Wound Signaling in Tomato Plants. Plant Physiol 2002; 130: 487-93.
101. Orozco-Cardenas ML, Narvaez-Vasquez J, Ryan CA. Hydrogen Peroxide Acts as a Second Messenger for the Induction of Defense Genes in Tomato Plants in Response to Wounding, Systemin, and Methyl Jasmonate. Plant Cell 2001; 13: 179-91.
102. Sobey CG, Miller AA. Signalling pathways activated by hydrogen peroxide in vascular smooth muscle. J Hypertens 2005; 23: 1961-2.
103. Park IJ, Hwang JT, Kim YM, et al. Differential Modulation of AMPK Signaling Pathways by Low or High Levels of Exogenous Reactive Oxygen Species in Colon Cancer Cells. Ann N Y Acad Sci 2006; 1091: 102-9.
104. Song Y, Driessens N, Costa M, et al. Roles of Hydrogen Peroxide in Thyroid Physiology and Disease. J Clin Endocrinol Metab 2007; 92: 3764-73.
105. Xing Y, Jia W, Zhang J. AtMKK1 mediates ABA-induced CAT1 expression and H2O2 production via AtMPK6-coupled signaling in Arabidopsis. Plant J 2008; 54: 440-51.
106. Ikeda Y, Taira K. Biologically Important Reactions Catalyzed by RNA Molecules. Chem Rec 2002; 2: 307-18.
107. Guglielmotto M, Giliberto L, Tamagno E, Tabaton M. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci 2010; 2: 3.